Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Patients who received 3 doses of pembrolizumab before surgery and 15 doses after surgery had significantly longer event-free survival than those who received adjuvant-only therapy with 18 doses after surgery.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 388; H. 9; S. 813 - 823
Hauptverfasser: Patel, Sapna P., Othus, Megan, Chen, Yuanbin, Wright, G. Paul, Yost, Kathleen J., Hyngstrom, John R., Hu-Lieskovan, Siwen, Lao, Christopher D., Fecher, Leslie A., Truong, Thach-Giao, Eisenstein, Jennifer L., Chandra, Sunandana, Sosman, Jeffrey A., Kendra, Kari L., Wu, Richard C., Devoe, Craig E., Deutsch, Gary B., Hegde, Aparna, Khalil, Maya, Mangla, Ankit, Reese, Amy M., Ross, Merrick I., Poklepovic, Andrew S., Phan, Giao Q., Onitilo, Adedayo A., Yasar, Demet G., Powers, Benjamin C., Doolittle, Gary C., In, Gino K., Kokot, Niels, Gibney, Geoffrey T., Atkins, Michael B., Shaheen, Montaser, Warneke, James A., Ikeguchi, Alexandra, Najera, Jose E., Chmielowski, Bartosz, Crompton, Joseph G., Floyd, Justin D., Hsueh, Eddy, Margolin, Kim A., Chow, Warren A., Grossmann, Kenneth F., Dietrich, Eliana, Prieto, Victor G., Lowe, Michael C., Buchbinder, Elizabeth I., Kirkwood, John M., Korde, Larissa, Moon, James, Sharon, Elad, Sondak, Vernon K., Ribas, Antoni
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 02.03.2023
Schlagworte:
Adjuvants
Adjuvants, Immunologic
Antineoplastic Agents, Immunological - administration & dosage
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Biopsy
Cancer therapies
Chemotherapy, Adjuvant
Coronaviruses
COVID-19
Dermatology
Disease Progression
Hematology
HIV
Human immunodeficiency virus
Humans
Immunotherapy
Lymphocytes
Melanoma
Melanoma - drug therapy
Melanoma - pathology
Melanoma - surgery
Metastasis
Monoclonal antibodies
Neoadjuvant Therapy
Oncology
Patients
Pembrolizumab
Radiation therapy
Review boards
Skin Cancer
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Skin Neoplasms - surgery
Surgery
Surgery General
Surgical outcomes
Survival
Targeted cancer therapy
Treatments in Oncology
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients who received 3 doses of pembrolizumab before surgery and 15 doses after surgery had significantly longer event-free survival than those who received adjuvant-only therapy with 18 doses after surgery.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2211437